secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-034876
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine
--------------------------------------------------------------------------------

- Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.
- Completed enrollment in Phase 2 START trial in early Alzheimer's; topline results expected in 2027.
- FDA Division of Psychiatry meeting anticipated by mid-2026 to discuss registrational plan for zervimesine in DLB psychosis.
- Launched expanded access program for DLB patients following a philanthropic donation.
- Appointed Dr. David Weinstein as VP of clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/0001104659-26-034876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/tm269805d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer